Chronic Pancreatitis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Kangen Pharmaceuticals, AzurRx BioPharma

September 15 08:13 2023
Chronic Pancreatitis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Kangen Pharmaceuticals, AzurRx BioPharma
DelveInsight Business Research LLP
DelveInsight’s “Chronic pancreatitis (CP) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Chronic pancreatitis (CP), historical and forecasted epidemiology as well as Chronic pancreatitis (CP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Chronic pancreatitis (CP) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Chronic pancreatitis (CP), historical and forecasted epidemiology as well as Chronic pancreatitis (CP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Highlights 

  • Key Companies working in Chronic Pancreatitis include Aptalis Pharma, Digestive Care Inc., Kangen Pharmaceuticals, AzurRx BioPharma, and many others.

  • Key Therapies included in the Chronic Pancreatitis market include Paricalcitol, Indomethacin, Indomethacin and many others 

Chronic Pancreatitis Overview

Chronic pancreatitis is a progressive inflammatory disorder that leads to irreversible destruction of exocrine and endocrine pancreatic parenchyma caused by atrophy and/ or replacement with fibrotic tissue. Functional consequences include severe abdominal pain, diabetes mellitus, and malabsorption. This activity describes the etiology, pathophysiology, evaluation, and management of chronic pancreatitis and highlights the role of an interprofessional team in the caring and rehabilitation of affected patients.

Chronic pancreatitis is a progressive inflammatory disease of the pancreas that affects both functions of the pancreas. For example, when the exocrine function is affected, patients will present with pancreatic insufficiency, steatorrhea, and weight loss. Pancreatic insufficiency results when greater than 90% of the organ is damaged. The incidence depends on the severity of the disease and can be as high as 85% in severe chronic pancreatitis. On the other hand, impairment of the endocrine function of the pancreas will eventually result in pancreatogenic diabetes (Type 3c diabetes).

Chronic Pancreatitis Epidemiology Insights

  • A recent epidemiological study in France found an annual incidence of 7.8 per 100,000. Assuming a survival of 15–20 years, the annual prevalence should be between 120 to 143 per 100,000. Overall, our understanding of the epidemiology of CP is poor compared with other illnesses.

  • Per 100,000 people in the general population, the yearly global incidence of acute pancreatitis is 34 cases, chronic pancreatitis is 10 cases and post-pancreatitis diabetes mellitus is 6 cases.

Click here to learn more about the Chronic Pancreatitis Market Landscape

The Report Covers the Chronic Pancreatitis Epidemiology Segmented by:

  • Chronic Pancreatitis prevalent cases 

  • Chronic Pancreatitis incident cases 

  • Chronic Pancreatitis treatment cases 

  • Chronic pancreatitis-diagnosed cases 

Chronic Pancreatitis Market Outlook 

The chronic pancreatitis (CP) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic pancreatitis (CP) market trends by analyzing the impact of current Chronic pancreatitis (CP) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Chronic pancreatitis (CP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chronic pancreatitis (CP) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Chronic pancreatitis (CP) market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Chronic Pancreatitis Market

  • Aptalis Pharma

  • Digestive Care Inc.

  • Kangen Pharmaceuticals

  • AzurRx BioPharma

And many others 

 

Chronic Pancreatitis Therapies Covered and Analyzed in the Report

  • Paricalcitol

  • Indomethacin

  • Creon36

  • RG1068

And many others 

Learn more about the Key Companies and Emerging Therapies in the Chronic Pancreatitis Market

Table of Contents 

  1.  Key Insights 

  2.  Chronic Pancreatitis Introduction 

  3.  Executive Summary of Chronic Pancreatitis           

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  Chronic Pancreatitis Emerging Therapies

  7.  Chronic Pancreatitis Market Outlook

  8.  Market Access and Reimbursement of Therapies

  9.  Market Drivers 

  10.  Market Barriers 

  11.  Appendix

  12.  Report Methodology

  13.  DelveInsight Capabilities

  14.  Disclaimer

Learn about the detailed offerings of the report @ Chronic Pancreatitis Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services